Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(50%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

completed150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_1

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

NCT01631942
completedphase_1

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

NCT01555749

Clinical Trials (2)

Showing 2 of 2 trials
NCT01631942Phase 1

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

Terminated
NCT01555749Phase 1

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Completed

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2